“We are encouraged not only by these preliminary results, but also by the level of collaboration in the Parkinson's community. These findings represent the efforts of pharmacologists, clinicians, statisticians, and clinical trial experts — including NINDS staff — who have come together with academia, industry, patients, and foundation groups to advance the development of innovative therapies for Parkinson's. The exceptional speed of patient recruitment allowed us to finish this study in record time.”
“We are encouraged not only by these preliminary results, but also by the level of collaboration in the Parkinson's community. These findings represent the efforts of pharmacologists, clinicians, statisticians, and clinical trial experts -- including NINDS staff -- who have come together with academia, industry, patients, and foundation groups to advance the development of innovative therapies for Parkinson's. The exceptional speed of patient recruitment allowed us to finish this study in record time.”
“We are encouraged not only by these preliminary results, but also by the level of collaboration in the Parkinson's community. These findings represent the efforts of pharmacologists, clinicians, statisticians, and clinical trial experts - including NINDS staff - who have come together with academia, industry, patients, and foundation groups to advance the development of innovative therapies for Parkinson's. The exceptional speed of patient recruitment allowed us to finish this study in record time.”
